ConjuChem Inc (CJB.TO) Buy, Sell or Hold

ConjuChem Inc (CJB.TO)

0.00

-0.00 (0.00%)

0 watching

DON'T BUY

Thinks it’s a horrible company. Last year they did $120 million of financing at $0.65. The $1 stock immediately plunged to $0.65. Last week they announced a $20 million financing at $0.15 convertible debenture. Has gone through $120 million in 12 months.

Wealthica Track your Stocks in your Watch List

DON'T BUY

Thinks it will bounce around a little bit. Not his favourite name. Continue to spend a lot of money and ultimately will have to come back to the market, perhaps some time next year. With the state of biotechs, both large and small, it is not a sector he would want to be in right now. Doesn't like the management.

WEAK BUY

Had a problem with nausea on their drug. Data is improving. Starting to fix the nausea problem. A very effective product. Did another financing, so they are well cashed up. Not the best management team.

WAIT

Was concerned when their drug was causing nausea, so they sold. Thinks they will have to do a lot of work. Will watch to see if they can solve the problem.

DON'T BUY

The nausea under the diabetes drug is fixable under certain conditions, but the question is can the do it. If they can fix, it's a very robust product and will have a very big market.

WAIT

Sold his holdings because of the convertible debenture issued. Too early to go back in. Expect their will be a lot of tax selling towards the end of the year and will look at it at that time.

DON'T BUY

The drop out rate on their diabetes drug was higher than expected. Wasn't happy the way management disseminated the information. Dead money in the near term.

WEAK BUY

Feels there is a potential drug here. Probably is near its bottom. A fair risk/reward. They are trying a new formulation re: nausea of the drugs they tested in phase 2 trials. Also waiting for a combination trial.

Wealthica Track your Stocks in your Watch List

DON'T BUY

Needs to know more before he would buy. Have to see better results in the future. Buy when it's rising.

TOP PICK

Not really happy with management. Took a big drop and is an interesting buy now. The drug works. Potential of being in phase three next year. Really cheap.

DON'T BUY

Not sure you should buy it at this time. You want to hold it when there is a possibility of approval being given for their product.

DON'T BUY

A negative report on patient's reactions created a drop in the stock. Drugs in phase one or phase two trials can be very volatile. Prefers larger companies.

BUY

An announcement is coming out next week and he thinks the news will be good, but would like it to be great. Speculative. Good management and balance sheet.

BUY

Stock has come off since they announced the successful trials on their diabetes applications. There is some risk, but has potential.

DON'T BUY

Has had a huge move. Has moved too far, too fast. Solid programs. Expensive.

Showing 1 to 15 of 23 entries

ConjuChem Inc (CJB.TO) Frequently Asked Questions

What is ConjuChem Inc stock symbol?

ConjuChem Inc is a OTC stock, trading under the symbol CJB.TO (previously CJB-T on Stockchase) on the undefined (undefined). It is usually referred to as or CJB.TO

Is ConjuChem Inc a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on CJB.TO (previously CJB-T on Stockchase) on Stockchase. Read the latest expert commentary for ConjuChem Inc.

Is ConjuChem Inc a good investment or a top pick?

ConjuChem Inc was recommended as a Top Pick by Glenn Paradis, BA, CFA on 2004-04-22. Read the latest stock experts ratings for ConjuChem Inc.

Why is ConjuChem Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for ConjuChem Inc.

Is ConjuChem Inc worth watching?

ConjuChem Inc is covered by Stockchase experts and is worth watching.

Most Recent Experts

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Gordon Reid

GoodReid Investment Counsel

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

ConjuChem Inc (CJB.TO)